Long-term safety study of BHV-7000 for hard-to-treat focal epilepsy
Tests whether BHV-7000 is safe over time in adults with hard-to-treat focal epilepsy.
Plain-language title generated from the registry record
Registry title: Long-term Safety and Tolerability of BHV-7000
Key facts
- Where
- Mexico City, Monterrey, Obispado, Sinaloa, Tlalnepantla, and Veracruz, MexicoSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06443463, who can take part
Where in Mexico
- Clinstile, S.A. de C.V.Mexico City, MexicoNo longer taking part
- Unidad de Investigación en Salud de Chihuahua S.C.-Mexico cityMexico City, MexicoNo longer taking part
- Accelerium, S. de R.L. de C.V. - PPDSMonterrey, MexicoNo longer taking part
- Axis Heilsa S. de R.L. de C.V.Obispado, MexicoNo longer taking part
- Neurociencias Estudios Clinicos S.C.Sinaloa, MexicoNo longer taking part
- Clinical Research Institute SC-MexicoTlalnepantla, MexicoNo longer taking part
- Faicic S de RL de CVVeracruz, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Biohaven Therapeutics Ltd.
- Trial code
- NCT06443463EU 2023-508813-18-00
- Record updated
- 1 May 2026
- Original description
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsyRead full original descriptionShow less
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Inclusion: Subjects who completed the double-blind phase (DBP) of prior parent study, BHV7000-302 or BHV7000-303; (FOCBP) Females of Child Bearing Potential must have a negative urine pregnancy test at the Baseline/Day 0 visit.
Exclusion: Any condition, such as an ongoing AE with/without sequelae, or is poorly tolerating IP in the double-blind phase of the parent study, that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator; Any medical condition, based on the judgement of the Investigator, that would confound the ability to adequately assess safety and efficacy outcome measures.